List of Excipients in Branded Drug TOPIRAMATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Upsher-Smith Laboratories LLC	TOPIRAMATE	topiramate	0832-1071	CELLULOSE, MICROCRYSTALLINE
Upsher-Smith Laboratories LLC	TOPIRAMATE	topiramate	0832-1071	DIETHYL PHTHALATE
Upsher-Smith Laboratories LLC	TOPIRAMATE	topiramate	0832-1071	ETHYLCELLULOSE
Upsher-Smith Laboratories LLC	TOPIRAMATE	topiramate	0832-1071	FERRIC OXIDE RED
Upsher-Smith Laboratories LLC	TOPIRAMATE	topiramate	0832-1071	FERROSOFERRIC OXIDE
Upsher-Smith Laboratories LLC	TOPIRAMATE	topiramate	0832-1071	HYPROMELLOSE 2910

Generic Drugs Containing TOPIRAMATE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	topiramate	0093-7335	AMMONIA
Teva Pharmaceuticals USA Inc	topiramate	0093-7335	ETHYLCELLULOSE
Teva Pharmaceuticals USA Inc	topiramate	0093-7335	FERROSOFERRIC OXIDE
Teva Pharmaceuticals USA Inc	topiramate	0093-7335	GELATIN
Teva Pharmaceuticals USA Inc	topiramate	0093-7335	POLYETHYLENE GLYCOL 6000
Teva Pharmaceuticals USA Inc	topiramate	0093-7335	POTASSIUM HYDROXIDE

What are the Most Frequently-Used Excipients in TOPIRAMATE?

# Of NDCs	Excipient
1	ALCOHOL
9	AMMONIA
92	ANHYDROUS LACTOSE
2	BUTYL ALCOHOL
1	CARBOXYMETHYLCELLULOSE CALCIUM
8	CELLULOSE ACETATE

Excipient Strategy and Commercial Opportunities for Topiramate

Last updated: February 28, 2026

What are the key excipient considerations for Topiramate formulations?

Topiramate is an anticonvulsant and migraine prevention drug administered orally. Its formulation depends heavily on excipient choices related to bioavailability, stability, and patient compliance. The drug’s physicochemical properties guide excipient selection: high lipophilicity and low water solubility influence formulation strategies. Common excipients include:

• Diluent Fillers: Microcrystalline cellulose, lactose monohydrate, and mannitol facilitate tablet formation and aid in accurate dosing.
• Binders: Cross-linked polyvinylpyrrolidone (PVP) enhances tablet cohesion.
• Disintegrants: Croscarmellose sodium enables rapid disintegration, improving absorption.
• Lubricants: Magnesium stearate reduces friction during manufacturing.
• Coating Agents: Hypromellose and film-forming polymers improve stability, mask taste, or modify release profiles.

Specialized formulations may incorporate:

• Extended-release matrices: Polyethylene oxide and hydroxypropyl methylcellulose (HPMC) for sustained absorption.
• Enteric coatings: Polyvinyl acetate phthalate for gastric protection where needed.

Formulation choices impact:

• Bioavailability: Excipient matrix influences dissolution rate.
• Stability: Protects against moisture, oxygen, or pH variations.
• Patient acceptability: Taste masking, ease of swallowing, and tablet size.

How do excipient choices influence the commercial landscape of Topiramate?

Excipient strategies directly affect manufacturing costs, patentability, and product differentiation. Companies can leverage formulation innovation to secure market exclusivity:

• Extended-release formulations: Patented matrices prolong dosing intervals, improving patient adherence and allowing premium pricing.
• Taste-masked formulations: Innovations catering to pediatric or sensitive populations expand market scope.
• Lower excipient load: Reducing excipients lowers production costs, beneficial for generic versions.

Additionally, the development of patent-protected delivery systems can create barriers to generic entry, prolonging revenue streams. The economic advantage hinges on differentiating formulations that meet regulatory standards for bioequivalence and safety.

What are the current regulatory and market implications?

Agencies like the U.S. FDA and EMA prioritize excipient safety, especially for special populations such as children or pregnant women. Regulatory pathways favor formulations with established excipient safety profiles, but novel excipients or delivery systems require extensive documentation.

Market trends show increasing demand for:

• Extended-release Topiramate: Offers once-daily dosing, aligning with patient compliance goals.
• Combination products: Pairing Topiramate with other anti-migraine agents or cognitive enhancers to improve treatment outcomes.
• Generic competition: Companies focus on innovative excipient use to patent new formulations and delay generic penetration.

The global market for Topiramate is projected to grow at a CAGR of 3.5% from 2022 to 2028 (Grand View Research, 2022). Formulation innovations, especially in sustained-release and combination forms, are key to capturing late-stage growth.

What are the commercial opportunities linked to excipient innovation?

• Patented Delivery Systems: Developing novel sustained-release matrices improves patent life and prevents early generic entry.
• Specialized Products: Taste-masked for pediatric use, or enteric-coated for specific indications, creates niche markets.
• Contract Manufacturing: Formulation outsourcing with excipient optimization can reduce costs for smaller pharmaceutical companies.
• Regulatory Advantages: Using well-characterized, Generally Recognized as Safe (GRAS) excipients simplifies approval processes.

Innovation pipelines focus on combining formulation robustness with patient-centric designs. Investments in novel excipients or delivery systems open opportunities for premium products and market differentiation.

Key Takeaways

• Excipient selection for Topiramate hinges on bioavailability, stability, and compliance.
• Formulation innovations such as extended-release or taste-masked products extend patent protection and market share.
• Industry trends favor sustained-release systems; regulatory agencies emphasize safety and compatibility.
• Market growth is driven by improved formulations offering convenience and improved adherence.
• Commercial success depends on balancing formulation innovation with regulatory approval, manufacturing costs, and patent strategies.

FAQs

1. How does excipient choice affect Topiramate bioavailability?
Excipient composition influences dissolution rate and absorption. Disintegrants like croscellulose enhance disintegration, increasing bioavailability; binders like PVP stabilize tablet integrity.

2. Can novel excipients extend Topiramate’s patent life?
Yes. Using proprietary excipients or delivery matrices can create patentable formulations, delaying generic competition.

3. What are common challenges in formulating Topiramate?
Topiramate’s low water solubility complicates achieving consistent bioavailability. Stability issues under moist conditions require protective excipients and coatings.

4. How does regulatory policy impact excipient use in Topiramate products?
Safety profiles of excipients are scrutinized; only GRAS-listed ingredients are favored unless new data supports safety.

5. What is the outlook for extended-release Topiramate products?
They are gaining market share, offering dosing convenience and adherence benefits. Companies investing in such formulations expect to capitalize on market demand.

---

References

[1] Grand View Research. (2022). Topiramate Market Size, Share & Trends Analysis Report.
[2] U.S. Food and Drug Administration. (2020). Guidance for Industry: Excipients in Approved Drug Products.